{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:28:53Z","timestamp":1787052533388,"version":"build-2736575974"},"reference-count":110,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elevated Lp(a) is an independent, causal, genetic cardiovascular disease risk factor that is associated with the progression of high-risk coronary plaques. Risk of atherosclerotic cardiovascular disease (ASCVD)-related conditions, which are among the leading causes of death worldwide, may persist in individuals with elevated Lp(a), even in the presence of at-target, guideline-recommended-low-density lipoprotein-cholesterol levels. The prevalence of premature ASCVD, often defined as an ASCVD event occurring in men &amp;lt;55 years old and in women &amp;lt;65 years old, is increasing, and several studies support Lp(a) playing a significant role in the development of premature ASCVD. Despite recognition of Lp(a) as a genetic risk factor for ASCVD and recommendations for universal Lp(a) testing in multiple clinical guidelines, Lp(a) testing occurs infrequently in clinical practice. In this review, we examine the role of elevated Lp(a) in premature cardiovascular events, including premature myocardial infarction, stroke, and peripheral arterial disease. We discuss the potential benefit of universal Lp(a) testing in the context of primary prevention to enable personalized risk assessment and to identify high-risk patients who may benefit from early and targeted management. Further, we evaluate ongoing systems initiatives aiming to a) address barriers to the adoption of universal Lp(a) screening, and b) enable the initiation of CV risk management for the prevention of premature ASCVD. Finally, we highlight the importance Lp(a) testing may play in secondary prevention, focusing on cascade screening for elevated Lp(a) in relatives of affected individuals.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwag313","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:57:00Z","timestamp":1784721420000},"source":"Crossref","is-referenced-by-count":0,"title":["The role of lipoprotein (a) in premature cardiovascular disease: primed for prevention"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-3752","authenticated-orcid":false,"given":"Maya S","family":"Safarova","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin , 8701 W Watertown Plank Road, Milwaukee, WI 53226 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-6370","authenticated-orcid":false,"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[{"name":"Emory Clinical Cardiovascular Research Institute and Emory University School of Medicine , Atlanta, GA ,","place":["USA"]},{"name":"The Family Heart Foundation , Fernandina Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-5551","authenticated-orcid":false,"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[{"name":"Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine , Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-2989","authenticated-orcid":false,"given":"Harpreet S","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-0723","authenticated-orcid":false,"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Center for Digital Health, and Cardiovascular Institute, Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026081806515311300_zwag313-B1"},{"key":"2026081806515311300_zwag313-B2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14797\/mdcvj.698","article-title":"The questions on everyone's mind: what is and why do we need preventive cardiology?","volume":"17","author":"Mahmood","year":"2021","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"2026081806515311300_zwag313-B3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"2026081806515311300_zwag313-B4","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026081806515311300_zwag313-B5","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026081806515311300_zwag313-B6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J"},{"key":"2026081806515311300_zwag313-B7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jacl.2024.11.007","article-title":"Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: a subanalysis from the lp(a)HERITAGE study","volume":"19","author":"Shapiro","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026081806515311300_zwag313-B10","doi-asserted-by":"crossref","first-page":"100940","DOI":"10.1016\/j.jacadv.2024.100940","article-title":"Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels","volume":"3","author":"Dudum","year":"2024","journal-title":"JACC Adv"},{"key":"2026081806515311300_zwag313-B11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamacardio.2023.1134","article-title":"Heterogeneity of lipoprotein(a) levels among Hispanic or latino individuals residing in the US","volume":"8","author":"Joshi","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026081806515311300_zwag313-B12","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae031","article-title":"Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"4","author":"Tian","year":"2024","journal-title":"Eur Heart J Open"},{"key":"2026081806515311300_zwag313-B13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"key":"2026081806515311300_zwag313-B14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/clinchem\/hvae007","article-title":"Plasma biomarker profiles for premature and nonpremature coronary heart disease in women","volume":"70","author":"Dugani","year":"2024","journal-title":"Clin Chem"},{"key":"2026081806515311300_zwag313-B15","doi-asserted-by":"crossref","first-page":"103843","DOI":"10.1016\/j.numecd.2024.103843","article-title":"Role of lipoprotein(a) in cardiovascuLar diseases and premature acute coronary syndromes (RELACS study): impact of lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease","volume":"35","author":"Cesaro","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026081806515311300_zwag313-B16","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/01.ATV.20.8.1998","article-title":"Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth","volume":"20","author":"McGill","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026081806515311300_zwag313-B17","article-title":"Atherosclerotic cardiovascular risk as an emerging priority in pediatrics","volume":"150","author":"Schipper","year":"2022","journal-title":"Pediatrics"},{"key":"2026081806515311300_zwag313-B18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022264","article-title":"Cardiovascular family history increases the risk of disease recurrence after a first myocardial infarction","volume":"10","author":"Wahrenberg","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026081806515311300_zwag313-B19","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.ajpc.2020.100040","article-title":"Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: we just cannot seem to get it right","volume":"2","author":"Toth","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11883-020-00862-8","article-title":"Premature atherosclerotic cardiovascular disease: what have we learned recently?","volume":"22","author":"Mahtta","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"2026081806515311300_zwag313-B21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00392-024-02427-0","article-title":"Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients - results from a large-scale multicentre registry in Germany","volume":"115","author":"Altmann","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026081806515311300_zwag313-B22","first-page":"200212","article-title":"The global burden of premature cardiovascular disease, 1990\u20132019","volume":"19","author":"Lababidi","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026081806515311300_zwag313-B23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12916-024-03527-4","article-title":"Comparative analysis of atherosclerotic cardiovascular disease burden between ages 20-54 and over 55 years: insights from the global burden of disease study 2019","volume":"22","author":"Li","year":"2024","journal-title":"BMC Med"},{"key":"2026081806515311300_zwag313-B24","first-page":"e1","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"26","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026081806515311300_zwag313-B25","first-page":"100350","article-title":"Lipoprotein(a): an important piece of the ASCVD risk factor puzzle across diverse populations","volume":"38","author":"Ciffone","year":"2024","journal-title":"Am Heart J Plus"},{"key":"2026081806515311300_zwag313-B26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026081806515311300_zwag313-B27","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B28","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"2026081806515311300_zwag313-B29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1210\/clinem\/dgab734","article-title":"Lipoprotein(a) levels at birth and in early childhood: the COMPARE study","volume":"107","author":"Strandkj\u00e6r","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081806515311300_zwag313-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0021-9150(92)90271-H","article-title":"Lipoprotein(a) at birth, in blacks and whites","volume":"92","author":"Rifai","year":"1992","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurjpc\/zwae341","article-title":"Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population","volume":"32","author":"Awad","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/diseases11040145","article-title":"Lipoprotein(a) and low-molecular-weight apo(a) phenotype as determinants of new cardiovascular events in patients with premature coronary heart disease","volume":"11","author":"Afanasieva","year":"2023","journal-title":"Diseases"},{"key":"2026081806515311300_zwag313-B35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2014.05.944","article-title":"Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting","volume":"235","author":"Ezhov","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European atherosclerosis society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ihj.2022.09.001","article-title":"Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography","volume":"74","author":"Chandra","year":"2022","journal-title":"Indian Heart J"},{"key":"2026081806515311300_zwag313-B38","doi-asserted-by":"crossref","first-page":"e014611","DOI":"10.1161\/CIRCIMAGING.122.014611","article-title":"Association of lipoprotein (a) with coronary-computed tomography angiography-assessed high-risk coronary disease attributes and cardiovascular outcomes","volume":"15","author":"Dai","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026081806515311300_zwag313-B39","first-page":"100382","article-title":"Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: an optical coherence tomography study","volume":"24","author":"Muramatsu","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026081806515311300_zwag313-B40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2025.04.013","article-title":"Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques: a PROSPECT II substudy","volume":"85","author":"Erlinge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B41","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.acvd.2021.10.009","article-title":"Lipoprotein(a): pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the nouvelle soci\u00e9t\u00e9 francophone d'Ath\u00e9roscl\u00e9rose (NSFA)","volume":"114","author":"Durlach","year":"2021","journal-title":"Arch Cardiovasc Dis"},{"key":"2026081806515311300_zwag313-B42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-3-031-24575-6_11","volume-title":"Lipoprotein(a)","author":"Safarova","year":"2023"},{"key":"2026081806515311300_zwag313-B43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"2026081806515311300_zwag313-B44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(99)00064-7","article-title":"Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux","volume":"143","author":"Nielsen","year":"1999","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B45","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1042\/BCJ20240037","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"481","author":"Boffa","year":"2024","journal-title":"Biochem J"},{"key":"2026081806515311300_zwag313-B46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B47","doi-asserted-by":"crossref","first-page":"117437","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B48","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.21037\/atm-20-5324","article-title":"Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia","volume":"9","author":"Cao","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026081806515311300_zwag313-B50","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"Wong","year":"2024","journal-title":"JACC"},{"key":"2026081806515311300_zwag313-B51","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.3390\/ijms24065927","article-title":"A systematic review on the risk modulators of myocardial infarction in the \u201cyoung\u201d\u2014implications of lipoprotein (a)","volume":"24","author":"St\u0103tescu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026081806515311300_zwag313-B52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/jpm12020269","article-title":"Lipoprotein(a), immune cells and cardiovascular outcomes in patients with premature coronary heart disease","volume":"12","author":"Afanasieva","year":"2022","journal-title":"J Pers Med"},{"key":"2026081806515311300_zwag313-B53","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur Heart J"},{"key":"2026081806515311300_zwag313-B54","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1177\/2047487320931296","article-title":"Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: the partners YOUNG-MI registry","volume":"28","author":"Berman","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B55","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2018.211433","article-title":"Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population","volume":"104","author":"Gabrielle","year":"2019","journal-title":"Haematologica"},{"key":"2026081806515311300_zwag313-B56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5603\/CJ.a2018.0106","article-title":"Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome","volume":"26","author":"Jubran","year":"2019","journal-title":"Cardiol J"},{"key":"2026081806515311300_zwag313-B57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosissup.2019.08.044","article-title":"Cardiovascular risk factors in patients with premature cardiovascular events attending the university of Dresden lipid clinic","volume":"40","author":"Schatz","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"2026081806515311300_zwag313-B58","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacl.2018.03.090","article-title":"Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease","volume":"12","author":"Chieng","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026081806515311300_zwag313-B59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2017.12.011","article-title":"High levels of lipoprotein (a) and premature acute coronary syndrome","volume":"269","author":"Rallidis","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jacl.2018.02.007","article-title":"Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease","volume":"12","author":"Verweij","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026081806515311300_zwag313-B61","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","article-title":"Impact of thrombophilia on risk of arterial ischaemic stroke or cerebral sinovenous thrombosis in neonates and children","volume":"121","author":"Kenet","year":"2010","journal-title":"Circulation"},{"key":"2026081806515311300_zwag313-B62","doi-asserted-by":"crossref","first-page":"101319","DOI":"10.1016\/j.ajpc.2025.101319","article-title":"Lipoprotein(a), family history, and incidence of premature ASCVD events in a pooled US cohort","volume":"24","author":"Fan","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B63","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034493","article-title":"Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the mass general brigham lp(a) registry","volume":"13","author":"Shiyovich","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026081806515311300_zwag313-B64","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.amjmed.2025.02.024","article-title":"The role of lipoprotein(a) in the progression of aortic stenosis","volume":"138","author":"Sherrill","year":"2025","journal-title":"Am J Med"},{"key":"2026081806515311300_zwag313-B65","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/CIRCRESAHA.111.300084","article-title":"Current management of calcific aortic stenosis","volume":"113","author":"Lindman","year":"2013","journal-title":"Circ Res"},{"key":"2026081806515311300_zwag313-B67","volume-title":"StatPearls","author":"Pujari","year":"2023"},{"key":"2026081806515311300_zwag313-B68","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026081806515311300_zwag313-B69","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"key":"2026081806515311300_zwag313-B70","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/biomedicines11071823","article-title":"Lipoprotein(a) as a potential predictive factor for earlier aortic valve replacement in patients with bicuspid aortic valve","volume":"11","author":"Krzesi\u0144ska","year":"2023","journal-title":"Biomedicines"},{"key":"2026081806515311300_zwag313-B71","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacasi.2024.07.007","article-title":"Association of lipoprotein(a) with severe degenerative aortic valve stenosis","volume":"4","author":"Kim","year":"2024","journal-title":"JACC Asia"},{"key":"2026081806515311300_zwag313-B72","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.12669\/pjms.35.6.377","article-title":"Serum lipoprotein (a) levels in acute coronary syndrome; comparison of younger and elderly patients with healthy controls","volume":"35","author":"Hanif","year":"2019","journal-title":"Pak J Med Sci"},{"key":"2026081806515311300_zwag313-B73","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31236","article-title":"The association between lipoprotein(a) levels and ischaemic stroke in children: a case-control study","volume":"71","author":"de Boer","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"2026081806515311300_zwag313-B74","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026081806515311300_zwag313-B75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archinte.1994.00420070129015","article-title":"Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men","volume":"154","author":"Valentine","year":"1994","journal-title":"Arch Intern Med"},{"key":"2026081806515311300_zwag313-B76","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026081806515311300_zwag313-B77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B78","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026081806515311300_zwag313-B79","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.15420\/ecr.2021.36","article-title":"Asian Pacific society of cardiology consensus recommendations on dyslipidaemia","volume":"16","author":"Koh","year":"2021","journal-title":"Eur Cardiol"},{"key":"2026081806515311300_zwag313-B80","doi-asserted-by":"crossref","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels international declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B81","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B82","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3949\/ccjm.92a.25020","article-title":"Lipoprotein(a) in clinical practice: what clinicians need to know","volume":"92","author":"Al-Dalakta","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"2026081806515311300_zwag313-B83","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.jacadv.2025.101826","article-title":"Prevalence and correlates of lipoprotein(a) testing in a diverse cohort of U.S. Adults","volume":"4","author":"Razavi","year":"2025","journal-title":"JACC Adv"},{"key":"2026081806515311300_zwag313-B84","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026081806515311300_zwag313-B85","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"key":"2026081806515311300_zwag313-B86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B87","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/eurjpc\/zwae382","article-title":"Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a)","volume":"32","author":"Razavi","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B88","doi-asserted-by":"crossref","first-page":"1727918","DOI":"10.3389\/fmed.2025.1727918","article-title":"Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction","volume":"12","author":"Alhomoud","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026081806515311300_zwag313-B89","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Ther"},{"key":"2026081806515311300_zwag313-B90","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081806515311300_zwag313-B91","first-page":"S10","article-title":"Lipoprotein(a) measurement \u2013 how, why and in whom?","volume":"31","author":"Ansari","year":"2024","journal-title":"Br J Cardiol"},{"key":"2026081806515311300_zwag313-B92","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1093\/eurheartj\/ehae191","article-title":"Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime","volume":"45","author":"Arsenault","year":"2024","journal-title":"Eur Heart J"},{"key":"2026081806515311300_zwag313-B93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B94","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/eurjpc\/zwab167","article-title":"Finding very high lipoprotein(a): the need for routine assessment","volume":"29","author":"Nurmohamed","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B95"},{"key":"2026081806515311300_zwag313-B96"},{"key":"2026081806515311300_zwag313-B97","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026081806515311300_zwag313-B98","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026081806515311300_zwag313-B99","first-page":"e219","article-title":"Use of risk assessment to guide decision-making for blood pressure management in the primary prevention of cardiovascular disease: a scientific statement from the American Heart Association and American College of Cardiology","volume":"152","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"2026081806515311300_zwag313-B100","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/biomedicines11061661","article-title":"Evidence and uncertainties on lipoprotein(a) as a marker of cardiovascular health risk in children and adolescents","volume":"11","author":"Genovesi","year":"2023","journal-title":"Biomedicines"},{"key":"2026081806515311300_zwag313-B101"},{"key":"2026081806515311300_zwag313-B102","doi-asserted-by":"crossref","first-page":"101274","DOI":"10.1016\/j.ajpc.2025.101274","article-title":"Lipoprotein(a) at a \u201ctipping point\u201d: case to move to universal screening","volume":"23","author":"Bhatia","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10508422.2012.728477","article-title":"Modern advances in genetic testing: ethical challenges and training implications for current and future psychologists","volume":"23","author":"Richmond-Rakerd","year":"2013","journal-title":"Ethics Behav"},{"key":"2026081806515311300_zwag313-B104","doi-asserted-by":"crossref","first-page":"101388","DOI":"10.1016\/j.ajpc.2025.101388","article-title":"Clinician awareness, testing, and treatment for lipoprotein(a): results from a large US national survey","volume":"25","author":"Wong","year":"2026","journal-title":"Am J Prev Cardiol"},{"key":"2026081806515311300_zwag313-B105","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1016\/j.jacl.2024.07.012","article-title":"Attitudes and barriers to lipoprotein(a) testing: a survey of providers at the university of Pennsylvania health system","volume":"18","author":"D'Souza","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026081806515311300_zwag313-B106","doi-asserted-by":"crossref","first-page":"119221","DOI":"10.1016\/j.atherosclerosis.2025.119221","article-title":"Editorial: the Brussels international declaration on lp(a) testing and management-A call to action","volume":"406","author":"Bor\u00e9n","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B107","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention","volume":"74","author":"Dixon","year":"2019","journal-title":"JACC"},{"key":"2026081806515311300_zwag313-B108","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2022.02.013","article-title":"How should public health recommendations address lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?","volume":"349","author":"Catapano","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026081806515311300_zwag313-B109"},{"key":"2026081806515311300_zwag313-B110","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1016\/j.hlc.2024.06.895","article-title":"Review of current clinical strategies of managing patients with elevated lipoprotein(a): cost-effectiveness of lp(a) testing and patient awareness of lifestyle changes through public health policy in absence of a targeted therapy","volume":"33","author":"Adams","year":"2024","journal-title":"Heart Lung Circ"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag313\/70473668\/zwag313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag313\/70473668\/zwag313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:52:10Z","timestamp":1787050330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag313\/8750578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag313","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"zwag313"}}